About this trial

Children with sickle cell disease (SCD) exhibit significantly reduced cognitive functioning (often difficulties with attention) compared to peers and siblings without SCD. EndeavorRx (Akili Interactive Labs: Boston, MA) is an FDA-approved home-based, electronic attentional-control training program designed to treat attention problems in youth. Users access EndeavorRx on a tablet device for 25-30 minutes each day, 5 days per week, for 4 weeks. The program involves training in a game-like environment that repeatedly challenges attentional-control abilities and adapts to user performance, becoming more difficult over time as performance improves. This pilot study is examining the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a sample of 20 children with SCD ages 8-16 who are being treated with chronic blood transfusion therapy.

Eligibility criteria

Qualifiers

diagnosis of SCD

ages 8-16 years

maintained on monthly blood transfusions consistently for at least 3 months.

patients will be proceed to the intervention phase only if they have a T-score > 75th percentile for Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) or a T-score > 75th percentile for the Inattention subscale of the ADHD Rating Scale, Fifth Edition (ADHD-RS-V).

Disqualifiers

estimated Intelligence Quotient < 70

motor, visual, or auditory impairment that prevents computer use

known diagnosis of a mental health condition that precludes, or takes treatment precedence over, participation in cognitive training

history of photosensitive seizures

Trial design

Treatments tested in this trial

  • EndeavorRx

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

1
Children's National Hospital20010, Washington D.C.District of Columbia, United States

Sponsors and collaborators

Children's National Research Institute

Lead sponsor